Jul. 24 at 1:26 PM
Nasdaq:
$ATRA
@Atarabio’ tab-cel has received FDA Priority Review for EBV+ PTLD, a rare post-transplant cancer. A decision is expected by Jan 15, 2025—potentially making it the first approved therapy for this life-threatening disease.
https://prismmarketview.com/atara-biotherapeutics-tab-cel-receives-fda-priority-review-for-ebv-post-transplant-lymphoproliferative-disease/